State records 31 new COVID-19 cases

Total fatalities stand at 3,739, while infections number 137,115. According to figures posted on Twitter by Health Minister Fahrettin Koca, 89,480 patients have recovered.

The association has written a letter to Minister of Housing and Urban Affairs Hardeep Singh Puri seeking his intervention in the matter

Bharti Airtel added Rs 8,537.95 crore to its m-cap to stand at Rs 2,89,144.54 crore

Leading scientists set out resource challenge of meeting net zero emissions in the UK by 2050  The Natural History Museum

The bacterial type VI secretion system (T6SS) secretes many toxic effectors to gain advantage in interbacterial competition and for eukaryotic host infection. The cognate immunity proteins of these effectors protect bacteria from their own effectors. PldB is a T6SS trans-kingdom effector in Pseudomonas aeruginosa that can infect both prokaryotic and eukaryotic cells. Three proteins, PA5086, PA5087 and PA5088, are employed to suppress the toxicity of PldB-family proteins. The structures of PA5087 and PA5088 have previously been reported, but the identification of further distinctions between these immunity proteins is needed. Here, the crystal structure of PA5086 is reported at 1.90 Å resolution. A structural comparison of the three PldB immunity proteins showed vast divergences in their electrostatic potential surfaces. This interesting phenomenon provides an explanation of the stockpiling mechanism of T6SS immunity proteins.

A peptide biphenyl hybrid compound {systematic name: dimethyl 2,2'-[((2S,2'S)-2,2'-{[(2S,2'S)-1,1'-([1,1'-biphen­yl]-2,2'-dicarbon­yl)bis­(pyrrolidine-1,2-diyl-2-carbon­yl)]bis­(aza­nedi­yl)}bis­(3-phenyl­propano­yl))bis­(aza­nedi­yl)](2S,2'S)-dipropionate hemihydrate}, C50H56N6O10·0.5H2O, was prepared by coupling of [1,1'-biphen­yl]-2,2'-dicarbonyl dichloride, tri­ethyl­amine and the tripeptide Pro–Phe–Ala in CH2Cl2 at 273 K under an N2 atmosphere. In the crystal, the asymmetric unit contains the peptide biphenyl hybrid accompanied by one-half of a water mol­ecule. A C atom of one of the proline rings is disordered between two positions in a 0.746 (11):0.254 (11) ratio. An important structural aspect of peptide compounds is their capacity to self-associate mediated by inter­molecular and intra­molecular hydrogen bonding. This characteristic can be useful in understanding the inter­actions between peptides and biomacromolecular targets, as well as to explain peptide properties.

Book review

The structure of the Pseudomonas aeruginosa T6SS PldB immunity protein PA5086 is reported at 1.9 Å resolution. Comparison of PA5086 with its homologs PA5087 and PA5088 showed great similarities in sequence and structure, but vast divergences in electrostatic potential surfaces.

While studying bats recently at the Academy of Natural Sciences in Philadelphia, Smithsonian mammalogist Kristofer Helgen discovered a new species of flying fox bat from […]

The post Smithsonian Scientist Discovers Two New Bat Species Hiding in Museum Collections for More Than 150 Years appeared first on Smithsonian Insider.

The stars move quickly because they are very close to each other, separated by only about one-fourth the distance from the Earth to the Moon. As a result, they share strong gravitational forces. They were once farther apart but have spiraled closer together over time. Billions of years from now, they will crash together and merge.

The post At 1,500,000 mph, twin stars in the constellation Cancer win speediest orbit award appeared first on Smithsonian Insider.

Collecting trips for Charles Doolittle Walcott (1850-1927), paleontologist and fourth Secretary of the Smithsonian Institution, were often a family affair. This 1910 photograph shows their […]

The post Charles Doolittle Walcott (1850-1927) family campsite in the Canadian Rockies appeared first on Smithsonian Insider.

The world’s coasts are home to more than 70 percent of the human population and experience intense development as a result. The rate of environmental […]

The post Smithsonian Environmental Research Center Marks 50 Years of Making a Difference appeared first on Smithsonian Insider.

New fossils found in Northeastern China have revealed a remarkable evolutionary coincidence: an extinct group of insects known as Kalligrammatid lacewings (Order Neuroptera) share an […]

The post Remarkable butterfly look-alike lived 50 million years before butterflies appeared appeared first on Smithsonian Insider.

More than 500 carats of rough diamonds were recently donated to the Department of Mineral Sciences of the Smithsonian’s Natural History Museum by Jewlers Mutual Insurance Co. of Neenah, Wis.

The post 500 carats of rough diamonds donated to Natural History Museum appeared first on Smithsonian Insider.

This new PBS Newshour video takes a look at a new exhibit at the Air and Space Museum celebrating NASA's space art program.

The post PBS Newshour takes a look at the new National Air and Space Museum exhibition “NASA | ART: 50 Years of Exploration” appeared first on Smithsonian Insider.

Time-lapse captured at the Hirshhorn Museum of Yayoi Kusama’s The Obliteration Room, on view in “Yayoi Kusama: Infinity Mirrors.” In Yayoi Kusama’s “The Obliteration Room,” […]

The post Adding 750,000 dots to The Obliteration Room appeared first on Smithsonian Insider.

President Barack Obama reiterated his strong support for science and technology today in a speech to members of the National Academy of Sciences at its 150th annual meeting.

Efforts to convert civilian research reactors from weapon-grade highly enriched uranium (HEU) to low enriched uranium (LEU) fuels are taking significantly longer than anticipated, says a congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

Source: Streetwise Reports   04/29/2020

Biopharmaceutical company Chimerix Inc. (CMRX:NASDAQ), which focuses on developing medicines to treat cancer and other serious diseases, today announced that it will initiate a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients suffering from acute lung injury (ALI).

The firm explained that "DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin.^"

Joseph Lasky, M.D., Professor of Medicine, Pulmonary and Critical Care Section Chief, John W. Deming, M.D. Endowed Chair in Internal Medicine at Tulane University Medical School commented, "Given the severity of the COVID-19 pandemic, we have evaluated many potential targets to address the clinical manifestations associated with severe COVID-19...Based on the literature, we believe DSTAT has the potential to reduce the excessive inflammation, immune cell infiltration and hypercoagulation associated with poor outcomes in patients with severe COVID-19 infection."

The company's CEO Mike Sherman remarked, " DSTAT is well-suited to unlock the anti-inflammatory properties of heparin as it may be dosed at much higher levels than any available form of heparin without triggering bleeding complications...We had planned to evaluate DSTAT in several indications of high unmet need, including ALI from different causes. The pandemic intensified our focus on ALI associated with COVID-19. Our team has worked closely with critical care physicians treating COVID-19 patients and with the U.S. Food and Drug Administration (FDA) to develop a Phase 2/3 protocol to determine if DSTAT can reduce the need for mechanical ventilation and improve the rate of survival in patients with severe COVID-19 infection."

The company outlined its plans for the study indicating that it will be a randomized, double-blind Phase 2/3 trial to determine the safety and efficacy of DSTAT in adults with severe COVID-19 who are at a high risk of respiratory failure. The study subjects will be confirmed COVID-19 patients who require hospitalization and supplemental oxygen therapy. The primary endpoint established in the study is the percentage of subjects who survive and do not require mechanical ventilation through 28 days. Several secondary endpoints listed include time needed for showing improvement, time to hospital discharge, time to resolution of fever, number of ventilator-free days, all-cause mortality and changes in several key biomarkers.

The study will begin by enrolling 24 subjects in Phase 2 to first establish dosage levels and then expand to 74 total patients. The firm advised that if Phase 2 results are positive, it would enroll approximately 450 subjects in the Phase 3 portion of the study.

The company reported that "the clinical manifestations of COVID-19 range from mild, self-limited respiratory tract illness to severe alveolar damage and progressive respiratory failure, multiple organ failure, and death. Mortality in COVID-19 is associated with severe pulmonary disease and coagulation disorders such as disseminated intravascular coagulation." The firm indicated that the mechanisms of action of DSTAT may address overactive inflammatory response including underlying causes of blood coagulation disorders associated with COVID-19.

Chimerix is a development-stage biopharmaceutical company based in Durham, N.C. which is engaged in advancing medicines in the areas of cancer and other serious diseases. The company listed that it presently has two active clinical-stage development programs. The first is dociparstat sodium (DSTAT) which is a glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity. The second pipeline candidate is brincidofovir (BCV) which is an antiviral drug being developed as a medical countermeasure for smallpox.

Chimerix began the day with a market capitalization of around $93.2 million with approximately 61.74 million shares outstanding. CMRX shares opened 30% higher today at $1.97 (+$0.46, +30.46%) over yesterday's $1.51 closing price. The stock has traded today between $1.82 to $2.62 per share and is currently trading at $2.27 (+$0.76, +50.33%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: CMRX:NASDAQ, )

The most comprehensive glacier assessment yet reveals that glacier melt was responsible for 27mm of sea level rise between 1961 and 2016. Ice loss from glaciers is now the second biggest contributor to rising sea levels after warming water. If glaciers continue to melt at current rates, most — including many in central Asia, central Europe, western Canada and the USA — will vanish during the second half of this century.

How can we grow more crops without taking too much water away from freshwater ecosystems for irrigation? A new study indicates that it is possible to double crop production by 2050 without exceeding set limits for water extraction if more crops are grown in regions with higher rainfall and with corresponding shifts in international trade and agricultural management. However, without appropriate safeguards, and if we follow the current business-as-usual scenario, this could come at the ecological cost of converting natural land and forest into cropland. This research provides a ‘first-step’ in analysing potential trade-offs in the global food-trade-water nexus.

Researchers from the University of Oxford's Bodleian Libraries and from universities in the Netherlands have used high-tech imaging to uncover the details of a rare Mexican codex dating from before the colonization of the Americas. The newly revealed codex, or book, has been hidden from view for almost 500 years, concealed beneath a layer of plaster and chalk on the back of a later manuscript known as the Codex Selden, which is housed at the Bodleian Libraries. Scientists have used hyperspectral imaging to reveal pictographic scenes from this remarkable document and have published their findings in the Journal of Archaeological Science: Reports.

read more

Extreme and catastrophic floods in Europe, such as those seen in 2013, currently occur approximately once every 16 years, but this may increase to once every 10 years by 2050, according to new research. The study also suggests that annual average economic losses caused by extreme floods could reach almost five times higher than 2013 values.

There are no technical or economic barriers to providing all of the world’s energy from renewable sources, according to a recent study. With a concerted effort, including reduced demand and international cooperation, the researchers suggest that the world could be entirely reliant on renewable energy for electric power, transportation and heating/cooling by 2050.

Renewable technologies could supply 77 per cent of the world demand for energy by 2050, according to a report recently published by the IPCC. However, strong and flexible national and international policies are needed to stimulate investment and encourage accelerated use of renewable energy. The most pessimistic scenarios see the renewables share remaining almost static until mid-century.

There is a large potential to improve the global efficiency of energy, land and phosphorus use, finds new research which modelled the effects of four worldwide scenarios between 2010 and 2050. An ‘ambitious resource strategy’ could moderate the increases in energy use (+25% globally instead of +80% in the baseline scenario), phosphorus use (+9% instead of +40%) and arable land (-9% globally, instead of + 4%).